title: Peroxisome proliferator-activated receptor alpha,gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice.
abstract: The apolipoprotein E (apoE) knockout mouse has provided an approach to the investigation of the effect of both cellular and humoral processes on atherosclerotic lesion progression. In the present study, pharmacologic modulation of both interferon gamma (IFNgamma)-inducible macrophage effector functions, and atherosclerotic lesions in the apoE knockout mouse were investigated using the peroxisome proliferator-activated receptor (PPAR) alpha,gamma coagonist LY465608. LY465608 inhibited, in a concentration-dependent manner, IFNgamma induction of both nitric oxide synthesis and the beta 2 integrin CD11a in elicited peritoneal macrophages from apoE knockout mice. Similar effects were observed ex vivo following 10 d of treating mice with 10 mg/kg of LY465608. Treatment of apoE knockout mice for 18 wk with LY465608 resulted in a statistically significant 2.5-fold reduction in atherosclerotic lesion area in en face aorta preparations. These effects were apparent in the absence of any reduction in total serum cholesterol or in lipoprotein distribution. Finally, treatment of apoF knockout mice with established atherosclerotic disease resulted in a modest but not statistically significant decrease in aortic lesional surface area. These results demonstrate the utility of PPAR coagonists in reducing the progression of the atherosclerotic lesion.
authors.affiliation: Division of Cardiovascular Research, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA. Zuckerman_Steven@Lilly.com
authors.forename: Steven H
authors.initials: SH
authors.lastname: Zuckerman
authors.forename: Raymond F
authors.initials: RF
authors.lastname: Kauffman
authors.forename: Glenn F
authors.initials: GF
authors.lastname: Evans
mesh_terms: D000818:Animals; D001011:Aorta / Q000187:drug effects; D001057:Apolipoproteins E / Q000172:deficiency* / Q000235:genetics; D001161:Arteriosclerosis / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D017353:Gene Deletion; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009930:Organic Chemicals; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists*; D014157:Transcription Factors / Q000819:agonists*
chemical_list: D001057:Apolipoproteins E; D007004:Hypoglycemic Agents; C453901:LY 465608; D009930:Organic Chemicals; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors